Naiyer A. Rizvi, MD, on Immunotherapy: Beyond Checkpoint Inhibition

Posted: Monday, March 20, 2017

Naiyer A. Rizvi, MD, of Columbia University Medical Center, discusses targeting immune suppression in the tumor microenvironment; therapy with engineered T cells, bispecific antibodies, and adoptive T-cell treatment; intramural therapies; and targeting neoantigens.